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Abstract
Aphids, among the most destructive insects to world agriculture, are mainly controlled by organophosphate insecticides that
disable the catalytic serine residue of acetylcholinesterase (AChE). Because these agents also affect vertebrate AChEs, they are
toxic to non-target species including humans and birds. We previously reported that a cysteine residue (Cys), found at the
AChE active site in aphids and other insects but not mammals, might serve as a target for insect-selective pesticides. However,
aphids have two different AChEs (termed AP and AO), and only AP-AChE carries the unique Cys. The absence of the active-site
Cys in AO-AChE might raise concerns about the utility of targeting that residue. Herein we report the development of a
methanethiosulfonate-containing small molecule that, at 6.0 mM, irreversibly inhibits 99% of all AChE activity extracted from
the greenbug aphid (Schizaphis graminum) without any measurable inhibition of the human AChE. Reactivation studies using
b-mercaptoethanol confirm that the irreversible inhibition resulted from the conjugation of the inhibitor to the unique Cys.
These results suggest that AO-AChE does not contribute significantly to the overall AChE activity in aphids, thus offering new
insight into the relative functional importance of the two insect AChEs. More importantly, by demonstrating that the Cys-
targeting inhibitor can abolish AChE activity in aphids, we canconclude thatthe uniqueCys maybe a viable target for species-
selective agents to control aphids without causing human toxicity and resistance problems.
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Introduction
Aphids are among the world’s most destructive insect pests of
grain crops, vegetables, ornamental plants, and fruit trees. For 150
years the greenbug aphid (Schizaphis graminum) has been a major
pest of small grains (e.g., sorghum and wheat). Annual costs for
greenbug control in wheat production have been estimated at up
to $100 million on the Texas High Plains alone [1]. The soybean
aphid (Aphis glycines) causes combined US yield losses and increased
production costs that exceed $1 billion [2]. Aphid control relies
mainly on a small number of highly toxic anticholinesterases
approved by the US Environmental Protection Agency (EPA); the
threat to agriculture and environmental health is growing. This
phenomenon is partly due to an unusual feature of aphid biology.
During the aphid-growing season all aphids become female, and
are able to produce offspring by maternal cloning in a process
known as parthenogenesis. This form of reproduction, with up to
18 asexual generations per growing season [3], allows aphids to
develop resistance rapidly when few effective insecticides are
applied repeatedly, as often happens in crops such as soybeans.
Acetylcholinesterase (AChE, EC 3.1.1.7) is a serine hydrolase
vital for regulating the neurotransmitter acetylcholine in mam-
mals, birds, and insects [4]. Current anticholinesterase insecticides
such as chlorpyrifos and methamidophos phosphorylate a serine
residue at the active site of AChE, thus disabling its function and
causing incapacitation. Because this serine residue is also present
in mammalian and avian AChEs, use of these insecticides poses
serious risks of toxicity to mammals, birds, and beneficial insects
such as the honeybee [5]. The US EPA has concluded that such
agents can enter the brain of fetuses and young children and may
damage the developing nervous system [6]. Controlling aphids in a
large field requires insecticides at quantities toxic to mammals and
birds. Unintended environmental toxicity is a concern associated
with current agents used to manage these insects. In light of this
concern, and the problem of insecticide resistance described
above, there is an urgent need for new agents that are both safer
and more effective in controlling aphids and related pests.
A new concept for insect control is to use an irreversible
inhibitor that targets an insect-specific region of an essential
protein in the target species. Sequence analyses of various insect
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4349proteins identified a cysteine residue that is absent in mammalian
[7–9] and avian [8,10] AChEs but conserved in the AChEs of
aphids and several other insects [7–9,11]. This sequence-based
finding was consistent with the reports that aphid AChEs were
sensitive to sulfhydryl inhibitors [12–16]. The sequence analysis
[7] along with the site-directed mutagenesis and molecular
modeling studies on an AChE from amphioxus (viz., an elongated
marine invertebrate) led to speculations (1) that the cysteine
residue conserved in the aphid AChE is located near the top of the
active-site gorge and sensitive to sulfhydryl inhibitors and (2) that
high affinity bi-functional cholinergic reagents that react tran-
siently with the active site serine and irreversibly with the cysteine
residue could be candidates for selective aphicides [7]. The three-
dimensional (3D) models of AChEs in the greenbug and the
English grain aphid (Sitobion avenae) generated by using terascale
computing were reported subsequently [9]. These models reveal
that the unique cysteine residue (Cys289 of the greenbug AChE or
its equivalent in the English grain aphid) is located at the entrance
of the AChE active site [9]. In the human AChE crystal structure
[17], the residue spatially corresponding to Cys289 is Val294
(Figure 1). Furthermore, according to the 3D models, Cys289 has
a favorable sulfur-aromatic interaction [18] with Tyr336 and is
accessible for covalent bonding to small molecules that bind at the
active site (Figure 2).
In general, a native or engineered cysteine residue near or at the
active site of an enzyme can ‘‘hook’’ (covalently bond to) a small
molecule that binds, even loosely, at the active site, as long as that
molecule carries a sulfhydryl moiety [19] or a leaving group that is
vulnerable to the attack by the thiol group [20]. Thus, a cysteine
proteinase can be inhibited selectively and irreversibly by a
chemically stable molecule via ‘‘hook chemistry,’’ namely, an
inhibitor binds near the cysteine residue and then forms an adduct
with that residue [20]. Worth noting here, sulfhydryl reagents,
including homologs [21] of the new irreversible methanethiosulfo-
nate-containing inhibitors disclosed in this article, reportedly form
adducts with a cysteine residue at the peripheral site of a
mammalian AChE engineered with a His287Cys mutation,
thereby interfering with substrate binding and catalytic activity
[21,22]. In fact, the alpha carbon atom of His287Cys in the
human AChE is 11 A ˚ away from that of Cys289 in the greenbug
AChE that is superimposed onto the human enzyme (see Figure 1).
Thus it is not an exact model for the insect case. However, these
Figure 1. Top view of an overlay of three-dimensional structures of the greenbug and human acetylcholinesterase from a
perspective looking down onto substrate acetylcholine at the catalytic site. The C, N, O, and S atoms are colored in yellow/green (human/
greenbug), blue, red, and orange, respectively. The theoretical model of the greenbug enzyme and the crystal structure of the human enzyme were
obtained from the coordinate files with Protein Data Bank codes of 2HCP and 1B41, respectively.
doi:10.1371/journal.pone.0004349.g001
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entrance of the AChE active site could be a suitable target. Below
we describe evidence for adducts with such a target in the native
greenbug AChE.
In this context, it appeared promising to use Cys289 or its
equivalent in other aphid AChEs as a novel target site for
insecticide development (Figure 2) [7–9,11–16,21,22]. Inhibitors
that target Cys289 should be less toxic to mammals than current
anticholinesterases, which target the ubiquitous catalytic serine
residue of all AChEs. Targeting Cys289 may alleviate resistance
problems with current insecticides for two reasons. First, aphids
and other insects have had no opportunity to develop resistance to
Cys289-targeting insecticides as they have done with the serine-
targeting agents that have been used for decades. Second, aphids
may find Cys289 indispensable even under selective pressure
because it stabilizes the conformations of key aromatic residues in
AChE. Indeed, sequence analysis shows that the AChEs of green
peach aphids (Myzus persicae) and cotton/melon aphids (Aphis
gossypii) carry the equivalent of Cys289 [8,9], although both aphids
are resistant to many current insecticides.
The fruit fly (Drosophila melanogaster), long used as a model insect,
has only one AChE gene [23]. Point mutations conferring
insecticide resistance in this gene have been identified [24].
However, in anticholinesterase-resistant strains of the house
mosquito (Culex pipiens) [25], no mutations were found in the gene
orthologous to the one in D. melanogaster, termed AO-AChE,
despite biochemical evidence of decreased AChE sensitivity to
current insecticides [26,27]. The inability to identify resistance-
conferring mutations in AO-AChE led to the two-AChE-gene
hypothesis that resistance-conferring mutations occur in an
unidentified gene, termed AP-AChE, that is paralogous to the
one in D. melanogaster [28]. This hypothesis was confirmed by the
discovery of the AP-AChE genes in the greenbug [11] and
subsequently in the malaria-carrying African mosquito (Anopheles
gambiae) [29]. Further studies suggested that AP-AChE is the
predominant form of AChE, expressed in the greenbug [28],
diamondback moth (Plutella xylostella) [30], human lice (Pediculus
humanus) [25], and insecticide-resistant mosquitoes (Culex tritaenior-
hynchus) [31].
Informed by this background, our previous sequence analysis of
the two AChE genes in insects showed that Cys289 in the
greenbug AP-AChE gene or its equivalent in other AP-AChE
genes is conserved in 16 insect species including aphids, but is
missing in the corresponding AO-AChE genes (see Figure S2 of
reference [9]). The reported preponderance of AP-AChE over
AO-AChE [25,28,30,31] supports the notion of Cys289 as a target
site for novel insecticides. However, an inhibitor selective for one
AChE gene might not be able to abolish all AChE activity in a
given insect. To address this concern while experimentally testing
the hypothesis that Cys-targeting compounds can be selective for
insect AChEs, we synthesized a series of methanethiosulfonate-
bearing inhibitors designed to have affinity for the AChE active
site and preferential reactivity with Cys289 or its equivalents in
insect AChEs. These agents were then compared in terms of their
ability to irreversibly inhibit AChE activity in extracts of the
greenbug and washed membranes from human red blood cells.
In this article, we report the development and initial
characterization of these inhibitors. Without precedent, one of
these, at 6.0 mM, caused 99% irreversible inhibition of total
extractable greenbug AChE activity while showing neither
reversible nor irreversible inhibition of the human AChE under
the same assay conditions. Below we discuss the implications of
Figure 2. Diagram representation of a methanethiosulfonate-bearing inhibitor (red) that reacts with Cys289 of the greenbug
acetylcholinesterase (blue) upon its binding at the active site.
doi:10.1371/journal.pone.0004349.g002
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AChEs in insects and the prospects for design of species-selective
insecticides.
Results
Design of Selective and Irreversible Aphid AChE
Inhibitors
To experimentally test the hypothesis that a species-specific
cysteine residue in aphids could be a target for novel insecticides,
we made a series of prototypical irreversible inhibitors (AMTS7–
AMTS20) shown in Figure 3. Inspired by reference [21], we
designed these inhibitors with (1) affinity for the greenbug AChE
active site in order to build up their local concentration around
Cys289 and (2) preferential reactivity to form an adduct with
Cys289 or its equivalent, at the entrance to the active site, after
binding near that locus (Figure 2). Therefore, all inhibitors of the
series contained (1) a trimethylammonium group to confer affinity
by the cation-pi interaction with Trp87 at the active site [32,33]
and (2) a methanethiosulfonate group known to form an adduct
preferentially with a free cysteine residue [34]. As an added design
feature, a chain of variable length separated the trimethylammo-
nium group from the reactive methanethiosulfonate group as a
means of controlling the access of the reactive group to Cys289 or
other nucleophiles. Our multiple 10-ns-long molecular dynamics
simulations of the greenbug AChE in complex with AMTS17
suggested that the 17-methylene-long inhibitor would tuck into the
active site with (1) its thiol sulfur atom located 3.6-A ˚ away from the
sulfur atom of Cys289 at the opening of the active site, while (2) its
ammonium group engages in an ionic interaction with Glu201 as
well as cation-pi interactions with Trp87, Tyr331, and Trp434 at
the bottom of the active site (Figure 4a).
Detecting Irreversible AChE Inhibition
Because only one of the two aphid AChEs carries a cysteine
residue at the entrance of the active site [8,9,11,28], the utility of
our proposed hook chemistry depended upon the percentage of
enzyme activity that could be irreversibly inhibited by the
sulfhydryl reagents. To measure this variable, we developed an
approach in which the total AChE-containing homogenate of
insect or mammalian samples was exposed to a candidate inhibitor
for a defined period of time, after which the unbound inhibitor was
removed from AChE by extended dialysis or centrifuge-spin
separation through a gel-filtration size-exclusion column (see
Methods, ‘‘Measurement of AChE inhibition’’). Assays of AChE
activity in the inhibitor-containing and inhibitor-free preparations,
when compared with a control, allowed us to determine the levels
of total and irreversible AChE inhibition, respectively. The assays
were performed under conditions that permitted accurate
determinations on sub-milligram samples (less than a single aphid),
using a radiometric method that was not influenced by free thiol
groups in samples or reagents.
Selective and Irreversible Inhibition of Aphid AChE
AMTS7–AMTS20 in concentrations from 1–100 mM were
tested on insect and human samples. One-hour exposures of these
compounds at a final concentration of 6.0 mM produced varying
AChE inhibition in extracts from the greenbug and human red
blood cells (RBCs). As expected, all the tested compounds
irreversibly inhibited 87–99% of the AChE activity in greenbug
extracts (Figure 5). In RBC extracts, by contrast, the short-chain
inhibitors (AMTS7–AMTS9) caused weak and purely reversible
inhibition at the same concentration. Somewhat surprisingly,
exposing the human enzyme to the mid-length inhibitors
(AMTS10–AMTS16) led to a degree of apparently irreversible
inhibition. AMTS13 was the most potent agent in this respect,
and hence least desirable. In one series of experiments, which
produced the data shown in Table 1, AMTS13 at 6.0 mM led to
43% inhibition after 1 hr, 70% after 6 hr, and 78% after 16 hr.
Gratifyingly, however, the long-chain inhibitors (AMTS17–
AMTS20) showed unprecedented AChE species-selectivity, caus-
ing only 0 to 2% inhibition of the RBC AChE (Figure 5) but 99%
inhibition of the greenbug enzyme.
Target for Irreversible Aphid AChE Inhibition
To confirm that the methanethiosulfonate-induced inhibition
was truly irreversible and not pseudo-irreversible (i.e., caused by
extremely slow dissociation), we studied a nonselective inhibitor
(AMTS13) and a selective inhibitor (AMTS18) in more detail. For
that purpose enzyme extracts of RBCs and the greenbug were
treated with AMTS13 or AMTS18 for 1 hour and then dialyzed
24, 72, and 200 hours with twice-daily changes of buffer (sodium
phosphate 0.1 M, pH 7.4). When AChE activity was subsequently
tested there was no time-dependent recovery of the greenbug
enzyme at any point. The effects of AMTS13 on both enzymes
were also stable over time. That is, the inhibitions of the greenbug
Figure 3. Chemical structures and synthetic schemes for AMTS7–AMTS20 as irreversible inhibitors of the greenbug
acetylcholinesterase.
doi:10.1371/journal.pone.0004349.g003
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4364%, respectively. Hence, with both enzymes the inhibition
was truly irreversible.
Subsequently, to investigate the nature of potential adducts that
caused the irreversible inhibition and their involvement of cysteine
residues in AChE, we performed reactivation experiments with
different concentrations of b-mercaptoethanol (BME) [34]. All the
following AMTS13 treatments involved prior inactivation by
AMTS13 (6.0 mM, 1 hr) followed by overnight dialysis. Low
concentrations of BME (1–10 mM) reactivated the greenbug
AChE weakly after an AMTS13 treatment (data not shown), but
100 mM BME was more effective in reactivation even though it
caused a minor loss of the AChE activity on its own. When fresh
greenbug and red cell extracts were treated for 0.5, 1.0, and
2.0 hours with 100 mM BME and then dialyzed (see Methods),
the human AChE activity fell to 36%, 31%, and 21% of the
control, respectively (Table 1). However, the greenbug AChE
pretreated with AMTS13 was dramatically reactivated by a two-
hour exposure to 100 mM BME. In fact, the enzyme recovered
from essentially zero activity (99% inhibition) to a level that was
76% of that in companion samples exposed only to BME (Table 1).
In contrast, the human AChE pretreated with AMTS13 did not
recover any enzymatic activity after the same BME treatment.
Instead, BME depressed the AChE activity of those samples even
further and substantially. These results confirm that the inhibition
of the greenbug AChE by AMTS13 was truly irreversible and
resulted from the conjugation of the [(Me)3N
+(CH2)13S2]
fragment of AMTS13 to the insect-specific Cys in the active site
of AP-AChE. The results also indicate that the partial irreversible
inhibition of the human AChE by the undesirable nonselective
AMTS13 involved a different mechanism, the exploration of
which lies beyond the focus of this paper. It is conceivable that the
long-chain inhibitors (AMTS17–AMTS20) are selective and
irreversible inhibitors of the aphid AChE that can pave the way
toward development of safer and more effective insecticides for
aphid control.
Discussion
Selective and Irreversible Inhibition of Aphid AChE
The present results provide direct experimental support for our
previously published hypothesis that targeting the insect-specific
cysteine residue can lead to safer and more effective insecticides
and thereby serve as the basis for production of species-selective
insecticides [8,9]. The long-chain inhibitors (AMTS17–AMTS20)
we developed to date achieved near total and essentially
permanent inhibition of the greenbug AChE at micromolar
concentrations of exposure while, under identical conditions, they
scarcely affected the corresponding enzyme in humans. Further-
more, our preliminary studies show that the long-chain inhibitors
also exhibited selective irreversible inhibition of total AChE
activity of soybean aphids (Aphis glycines) at an inhibitor
concentration of 6.0 mM (data not shown).
It is worth noting, however, these inhibitors are prototypes that
are not necessarily suitable for field application. As yet they have
not been tested to determine the relationship between the effective
inhibitory concentration and the reaction time as well as their
toxicity at a chosen concentration to aphids or other target species,
or to confirm their predicted safety for mammals and birds.
Likewise, there is no information regarding the physical stability of
these methanethiosulfonates under field conditions or their
persistence in soil and groundwater. Nonetheless, we regard the
in vitro demonstration of species selectivity and essentially
permanent inhibition of insect AChEs by our prototypes as not
only proof of concept but also an exceedingly promising beginning
to search for conceptually new insecticides that will be useful in
agriculture while posing less environmental risk than current
insecticides.
Figure 4. Cross-section view of the multiple-molecular-dynamics-simulation-refined three-dimensional models of the greenbug
and human acetylcholinesterases in complex with AMTS17 and AMTS13, respectively. Left: The C, N, O, and S atoms are colored in
magenta/green (AMTS17/AChE), blue, red, and yellow, respectively. Right: The C, N, O, and S atoms are colored in green/yellow (AMTS13/AChE),
blue, red, and yellow, respectively.
doi:10.1371/journal.pone.0004349.g004
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The functional roles of insect AO-AChE and AP-AChE are still
unclear, partly because it was not formerly possible to inactivate
either gene product selectively. However, the results described
above suggest that AP-AChE will prove to be functionally more
important, at least in the greenbug. The AO-AChE of aphids does
not carry a cysteine residue at the active site according to our
reported sequence analysis of AChE genes in insects [8]. As
demonstrated in the present study, AMTS18 do not reversibly or
irreversibly inhibit the human AChE, and hence these compounds
should not irreversibly inactivate the aphid AO-AChE. In other
words, these compounds are plausible selective and irreversible
inhibitors of the aphid AP-AChE, and yet they irreversibly
inactivated 99% of the total AChE activity in our greenbug
extracts. We see two possible explanations for this observation: (1)
AO-AChE is poorly extracted and not measured in our assay; (2)
AO-AChE is a minor contributor to the total acetylcholine-
hydrolysis activity in the greenbug. The first explanation appears
unlikely for several reasons. First, our extraction conditions used
extensive mechanical homogenization to create fine suspensions
from greenbug samples, in which all of the AChE should have
been accessible to substrate. Second, our assays were performed
directly on the suspensions without first removing insoluble matter
by centrifugation or filtration. And third, in preliminary
experiments with the fruit fly, whose well-characterized genome
includes only the active-site-cysteine-free AO-AChE [23], the
identical extraction protocol rendered abundant fruit fly AChE
activity that was resistant to AMTS18. Therefore, we infer that
the greenbug AO-AChE is indeed resistant to AMTS18 and,
hence, that this enzyme form does not contribute significantly to
the total acetylcholine-hydrolyzing activity in the greenbug.
Species-Selective Insecticide Targets
After sequence analysis of AChEs in 73 species [8,9] we
reported that Cys289 or its equivalent is absent in mammalian
AChE but is conserved in the AP-AChE gene of 16 insects: house
mosquito, Japanese encephalitis mosquito (Culex tritaeniorhynchus),
the malaria-carrying African mosquito, German cockroach
(Blattella germanica), rice leaf beetle (Oulema oryzae), cotton bollworm
(Helicoverpa armigera), beet armyworm (Spodoptera exigua), codling
moth (Cydia pomonella), diamondback moth (Plutella xylostella),
domestic silkworm (Bombyx mori), honeybee (Apis mellifera), bird
Figure 5. Inhibition of the greenbug and human AChEs by AMTS7–AMTS20. Extracts of greenbugs and human RBCs in 0.1 M sodium
phosphate buffer (see Methods) were exposed to AMTS7–AMTS20 at 6.0 mM for one hour at room temperature. Radiometric assays were used to
determine AChE activity in aliquots of treated samples either immediately (empty symbols) or after overnight dialysis with 2 changes of buffer in 100-
fold excess (filled symbols). The difference between the paired measurements (i.e., the recovery after dialysis) indicates reversible inhibition.
doi:10.1371/journal.pone.0004349.g005
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aphid, green peach aphid, and English grain aphid. Except for the
honeybee and silkworm, all others are pests. We found that the
recently determined AP-AChE of the yellow fever mosquito (Aedes
aegypti) also carries the active-site cysteine residue (unpublished
result). The AP-AChE genes from additional pests will likely be
determined in the near future. This outcome should add impetus
to the increasingly well-validated pesticide strategy of targeting
insect-specific cysteine residue.
Cysteine-targeting inhibitors like those described here should be
far superior to current anticholinesterases in their lack of (1)
resistance currently established in insects and (2) harm to no-target
organisms. However, like current anticholinesterases cysteine-
targeting inhibitors pose potential risks to the honeybee and
silkworm, which also carry the insect-specific cysteine residues.
Fortunately, there are realistic prospects for designing inhibitors
with greater specificity within this broad group of organisms.
Targeting another insect-specific residue in addition to Cys289 or
its equivalent might minimize toxicity to bees or silkworms. In fact,
we recently identified a second residue as a possible species-specific
target in insects. This residue, Arg339 of the malaria-carrying AP-
AChE, is absent in mammals and many insects but conserved at
the entrance of the AP-AChE active site in the malaria-carrying
African mosquito, the house mosquito, the Japanese encephalitis
mosquito, and the German cockroach [8]. Our new analysis shows
that the unique arginine residue is conserved in the yellow fever
mosquito AP-AChE as well. It is logical to expect that targeting
both Cys286 and Arg339 of A. gambiae AP-AChE could lead to
specific ‘‘mosquitocides’’ that spare mammals, birds, honeybees,
silkworms, and other beneficial insects. As to the aphid control, the
species-selective insecticide strategy described above can be
extended to targeting a residue in aphid AChEs that adopts a
unique conformation in the 3D aphid AChE structures (which we
refer to as an ‘‘aphid-conformation’’ residue) in comparison to the
same residue in AChEs of other species. Targeting both aphid-
specific and aphid-conformation residues could avoid the toxicity
to beneficial insects.
Possible Reaction of AMTS13 with Activated Serine
The mechanism by which AMTS13 causes partial but
persistent inhibition of the human AChE is worth discussing,
although it is not directly pertinent to our aim of developing
selective and irreversible inhibitors of insect AChEs. Methanethio-
sulfonates are known to react preferentially with cysteine over
other residues [34] and are widely used as probes to distinguish
cysteine from serine [35–37]. On the other hand, there is no free
cysteine residue in the active site of the human AChE. Six of the
eight cysteine residues in human AChE [38] are oxidized to form
intrasubunit disulfide bonds according to the crystal structure of
the human AChE [17]; the remaining two are located at the N-
and C-termini, respectively [38] but the N-terminal cysteine
residue is removed during biosynthesis [39] while the C-terminal
one forms an intersubunit disulfide bond [40]. The observation of
43% irreversible inhibition of the human AChE by AMTS13 was
therefore puzzling.
As apparent from Figure 5, the irreversible inhibition of the
human AChE is far more sensitive to the chain lengths of the
inhibitors than the corresponding inhibition of the greenbug
enzyme; nearly two-fold more irreversible inhibition was observed
with the insect enzyme than with the human enzyme at the same
assay conditions. These results suggested that the residue that
reacts with AMTS13 in the human AChE was much less reactive
than Cys298 in the greenbug AChE. A residue in the human
AChE whose reactivity may fall in that category is Ser203, which
is activated for nucleophilic reactions by nearby His447 and
Glu334 through a network of hydrogen bonds [17], although
methanethiosulfonates do not react with ‘‘ordinary’’ serine
residues [34–37].
Table 1. Reactivation Studies of the Greenbug and Human Acetylcholinesterases (AChEs) Inhibited by AMTS13 Using b-
Mercaptoethanol (BME) That Can Reverse the AMTS13 Inhibition and Concomitantly Denature the Disulfide-Containing AChEs.
Sample Pretreatment Treatment % AChE activity
% AChE activity reduced
by BME and/or AMTS13
% AChE activity
recovered by BME
Greenbugs None None 100 0
’’ BME 0.5 hr 36 64
’’ BME 1 hr 31 69
’’ BME 2 hr 21 79
AMTS13 None 1 99 0
’’ BME 0.5 hr 12 88 33
’’ BME 1 hr 17 83 55
’’ BME 2 hr 16 84 76
RBCs None None 100 0
’’ BME 0.5 hr 49 51
’’ BME 1 hr 44 56
’’ BME 2 hr 35 65
AMTS13 None 57 43 0
’’ BME 0.5 hr 28 72 0
’’ BME 1 hr 26 74 0
’’ BME 2 hr 20 80 0
The greenbug and RBC extracts were exposed to AMTS13 (6.0 mM) for 1 hr and/or to BME (100.0 mM) for different periods of time. After the exposure(s), samples were
dialyzed overnight and the AChE activity was measured. Activities are mean values of triplicate determinations expressed as percentages of the AChE activity.
doi:10.1371/journal.pone.0004349.t001
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human AChE in complex with AMTS13 suggest that the inhibitor
is able to span the active site with (1) its thiol sulfur atom located
5.0-A ˚ away from the Ser203 hydroxyl oxygen atom and (2) its
ammonium group engaged in an ionic interaction with E285 and
cation-pi interactions with Tyr124 and Trp286 (Figure 4b). Our
model reaction of AMTS13 with 34 equivalents of CD3ONa also
showed instant formation of 13-[methoxythio(d3)]-N,N,N-tri-
methyltridecan-1-aminium bromide at room temperature. The
resulting sulfenate ester (Me3N
+(CH2)13-S-O-CD3) was found to
be stable at room temperature under the basic condition, which is
consistent with the report of aliphatic sulfenate esters [41]. These
results support the hypothesis that AMTS13 reacts with the
catalytic serine residue in the human enzyme. Our simulations also
revealed that the side-chain conformation of Trp86 in the human
AChE bound with AMTS13 is very different from the
conformation in the free enzyme, implying a high-energy cost
associated with the binding of AMTS13. This feature may
account for the fact that only 43% of the human AChE was
irreversibly inhibited by a one-hour exposure to AMTS13.
Structural studies with liquid chromatography mass spectrometry
and/or crystallography analysis are needed to confirm the posited
adduct of AMTS13 to Ser203 in the human AChEs. Further
studies are also needed to investigate the possibility that AMTS13
may form micelles at 6.0 mM and partially inhibit human AChE
through enzyme denaturation. Meanwhile, the present results do
raise caution with regard to the use of methanethiosulfonate-based
agents to probe cysteine residues in the presence of a serine residue
that is activated for nucleophilic reactions.
Materials and Methods
Sources
Greenbugs were obtained from the Department of Entomology
at Kansas State University. Soybean aphids were collected from
demonstration plots at the University of Minnesota Extension
facility in Rochester, Minnesota. Fruit flies were received from Dr.
A. Tang in Transplant Biology at the Mayo Clinic. Group AB
human red blood cells were obtained from Sigma-Aldrich (St
Louis, MO) as were b-mercaptoethanol, and acetylcholine iodide.
Tritiated acetylcholine (99 mCi/mM) was purchased from New
England Nuclear (Waltham, MA). AMTS7–AMTS20 were
synthesized as described below.
Chemical Syntheses
The
1Ha n d
13C NMR spectra were recorded on a Varian
Mercury 400 spectrometer. Chemical shifts are reported in ppm
using either tetramethylsilane or the solvent peak as an internal
standard. Data are reported as follows: chemical shift, multiplicity
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet), cou-
pling constant and integration. Elemental analyses were performed
by Atlantic Microlab, Inc. (Norcross, Georgia). Medium Pressure
Liquid Chromatography (MPLC) was performed with Biotage SP-1
(Charlottesville, VA) using silica gel (EM Science, 230–400 mesh).
T r i m e t h y l a m i n e( 3 3 %w / ws o l u t i o ni ne t h a n o l ) ,1 , 8 - d i b r o m o o c t a n e ,
1,10-dibromodecane, 1,11-dibromoundecane and 1,12-dibromodo-
decane were purchased from Acros Organics (Geel, Belgium). 1,7-
Dibromoheptane and 1,9-dibromononane were purchased from
Aldrich Chemical Company, Inc. (Milwaukee, WI). 1,14-Dibromo-
tetradecane was purchased from Pfaltz & Bauer, Inc. (Waterbury,
CT). 13-Bromo-1-tridecanol, 15-bromo-1-pentadecanol and 16-
bromo-1-hexadecanol were purchased from AstaTech, Inc. (Bristol,
PA). Other 1,n-dibromoalkanes (where n=17–20) [42,43] and
sodium methanethiosulfonate [44] were synthesized following
literature procedures. 10-Bromo-N,N,N-trimethyldecan-1-aminium
bromide [45], 12-bromo-N,N,N-trimethyldodecan-1-aminium bro-
mide [45], 15-hydroxy-N,N,N-trimethylpentadecan-1-aminium bro-
mide [46] and 16-hydroxy-N,N,N-trimethylhexadecan-1-aminium
bromide [46] were synthesized following literature procedures.
Procedure i: Synthesis of n-hydroxy-N,N,N-trimethylalkan-
1-aminium bromide
Trimethylamine (33% w/w solution in ethanol, excess 20–100
eq) was added to n-bromoalkan-1-ol (1 eq) and left for 24 h. The
solid obtained was collected by filtration, washed with hexanes/
ethyl acetate mixtures (9/1, 363 mL/mmol) in a sonicator. The
residue was filtered and dried to give n-hydroxy-N,N,N-trimethy-
lalkan-1-aminium bromide.
Procedure ii: Synthesis of n-bromo-N,N,N-trimethylalkan-
1-aminium bromide
Hydrobromic acid (48% aqueous, 10 mL/mmol) and toluene
(10 mL/mmol) were added to n-hydroxy-N,N,N-trimethylalkan-1-
aminium bromide and refluxed using a Dean-Stark apparatus till
no more water was collected (12–24 h). Toluene was removed
under vacuum, and the residue was sonicated in a mixture of
hexanes/ethyl acetate (9/1, 3610 mL/mmol) and filtered to give
n-bromo-N,N,N-trimethylalkan-1-aminium bromide.
Procedure iii: Synthesis of n-bromo-N,N,N-trimethylalkan-
1-aminium bromide
Trimethylamine (1 eq, 33% w/w solution in ethanol) was added
dropwise to the 1,n-dibromoalkane (1.2 eq) in toluene (0.1 mL/
mmol) and left aside in the dark for 48 h. The solid formed was
collected by filtration and triturated with acetone (2630 mL). The
combined acetone layer was concentrated and dried to give n-
bromo-N,N,N-trimethylalkan-1-aminium bromide.
Procedure iv: Synthesis of S-n-bromoalkyl
methanesulfonothioate
Sodium methanethiosulfonate (1 eq) was added to a clear
solution of 1,n-dibromoalkane (5 eq) (longer chain analogues
needed slight warming for complete dissolution) in dimethylfor-
mamide or acetonitrile (3 mL/mmol) and the mixture heated at
55uC for 20 h. The cooled reaction mixture was poured into water
(3 mL/mmol) and extracted with ethyl acetate (363 mL/mmol).
The combined organic layer was dried over anhydrous magne-
sium sulfate, concentrated under vacuum and refined by MPLC
(gradient from 0 to 20% ethyl acetate in hexanes) to give S-n-
bromoalkyl methanesulfonothioate.
Procedure v: Synthesis of N,N,N-trimethyl-n-
(methylsulfonylthio)alkan-1-aminium bromide
The n-bromo-N,N,N-trimethyl-n-alkan-1-aminium bromide (1
eq) and sodium methanethiosulfonate (0.95–1.10 eq) were refluxed
in methanol (5–10 mL/mmol) for 24–48 h. The reaction mixture
was cooled and concentrated under vacuum. The residue was
sonicated in acetone. The insolubles (sodium bromide) were
filtered and the filtrate was concentrated under vacuum. The
concentrated filtrate was sonicated in hexanes (20 mL/mmol) and
the solid collected by filtration to give the product, which was
purified by recrystallization from acetone.
Procedure vi: Synthesis of N,N,N-trimethyl-n-
(methylsulfonylthio)alkan-1-aminium bromide
S-n-Bromoalkyl methanesulfonothioate (1 eq) was treated with
excess trimethylamine (33% w/w solution in ethanol, 30–100 eq)
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vacuum and the residue was sonicated in hexanes (20 mL/mmol)
and the solid was collected by filtration to give the product, which
was purified by recrystallization from acetone.
7-Bromo-N,N,N-trimethylheptan-1-aminium bromide
(331 mg, 6%) was obtained from 1,7-dibromoheptane (5.14 g,
20 mmol) and trimethylamine (4 mL, 33% w/w solution in
ethanol, 16.74 mmol) following procedure iii.
1H NMR (CDCl3):
3.62–3.58 (m, 2H), 3.42 (s, 9H), 3.38 (t, J=6.6 Hz, 2H), 1.84–1.77
(m, 2H), 1.76–1.70 (m, 2H), and 1.44–1.31 (m, 6H);
13C NMR
(CDCl3): 66.6, 53.3, 33.9, 32.3, 28.1, 27.6, 25.8, and 22.9.
N,N,N-Trimethyl-7-(methylsulfonylthio)heptan-1-ami-
nium (AMTS7, 174 mg, 19%) was obtained from sodium
methanethiosulfonate (388 mg, 2.89 mmol) and 7-bromo-N,N,N-
trimethylheptan-1-aminium bromide (830 mg, 2.62 mmol) follow-
ing procedure v.
1H NMR (DMSO-d6): 3.53 (s, 3H), 3.31–3.27 (m,
2H), 3.21 (t, J=7.2 Hz, 2H), 3.05 (s, 9H), 1.74–1.62 (m, 4H),
1.44–1.33 (m, 4H), and 1.31–1.22 (m, 2H);
13C NMR (DMSO-d6):
65.9, 52.8, 50.8, 36.1, 29.4, 28.5, 28.3, 26.2, and 22.6; Anal. Calcd
(%) for C11H26NO2S2 Br: C 37.93, H 7.52, and N 4.02; Found: C
37.63, H 7.46, and N 4.06.
S-8-Bromooctyl methanesulfonothioate (560 mg, 86%)
was obtained from sodium methanethiosulfonate (288 mg,
2.15 mmol) and 1,8-dibromooctane (2.82 g, 10.37 mmol) follow-
ing procedure iv.
1H NMR (CDCl3): 3.41 (t, J=6.8 Hz, 2H), 3.33
(s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.89–1.82 (m, 2H), 1.81–1.73 (m,
2H), and 1.48–1.32 (m, 8H);
13C NMR (CDCl3): 50.9, 36.7, 34.2,
32.9, 29.7, 29.0, 28.7, and 28.2.
N,N,N-Trimethyl-8-(methylsulfonylthio)octan-1-ami-
nium bromide (AMTS8, 236 mg, 76%) was obtained from
trimethylamine (33% w/w solution in ethanol, 30 mL) and S-8-
bromooctyl methanesulfonothioate (260 mg, 0.85 mmol) following
procedure vi.
1H NMR (CDCl3): 3.67–3.62 (m, 2H), 3.45 (s, 9H),
3.37 (s, 3H), 3.19 (t, J=7.4 Hz, 2H), 1.82–1.74 (m, 4H), and 1.48–
1.34 (m, 8H);
13C NMR (CDCl3): 66.9, 53.6, 51.0, 36.6, 29.4,
29.0, 28.7, 28.3, 26.1, and 23.2.
S-9-Bromononyl methanesulfonothioate (480 mg, 71%)
was obtained from sodium methanethiosulfonate (268 mg,
2.14 mmol) and 1,9-dibromononane (2.86 g, 10.0 mmol) follow-
ing procedure iv.
1H NMR (CDCl3): 3.41 (t, J=6.8 Hz, 2H), 3.32
(s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.89–1.82 (m, 2H), 1.80–1.73 (m,
2H), 1.42 (m, 6H), and 1.31 (m, 4H);
13C NMR (CDCl3): 50.9,
36.7, 34.3, 33.0, 29.7, 29.4, 29.1, 28.8, 28.7, and 28.3.
N,N,N-Trimethyl-9-(methylsulfonylthio)nonan-1-ami-
nium bromide (AMTS9, 212 mg, 66%) was obtained from
trimethylamine (33% w/w solution in ethanol, 30 mL) and S-9-
bromononyl methanesulfonothioate (270 mg, 0.85 mmol) follow-
ing procedure vi.
1H NMR (CDCl3): 3.64–3.60 (m, 2H), 3.45 (s,
9H), 3.36 (s, 3H), 3.18 (t, J=7.2 Hz, 2H), 1.81–1.73 (m, 4H), and
1.44–1.33 (m, 10H);
13C NMR (CDCl3): 67.0, 53.6, 50.9, 36.7,
29.5, 29.1, 28.8, 28.4, 26.2, and 23.3.
N,N,N-Trimethyl-10-(methylsulfonylthio)decan-1-ami-
nium bromide (AMTS10, 60 mg, 23%) was obtained from
sodium methanethiosulfonate (103 mg, 0.77 mmol) and 10-
bromo-N,N,N-trimethyldecan-1-aminium bromide (238 mg,
0.66 mmol) following procedure v.
1H NMR (DMSO-d6): 3.52
(s, 3H), 3.30–3.26 (m, 2H), 3.20 (t, J=7.4 Hz, 2H), 3.05 (s, 9H),
1.74–1.62 (m, 4H), and 1.40–1.22 (m, 12H);
13C NMR (DMSO-
d6): 65.9, 52.8, 50.8, 36.2, 29.5, 29.4, 29.1, 29.0, 28.5, 26.4, and
22.7.
S-11-Bromoundecyl methanesulfonothioate (350 mg,
60%) was obtained from sodium methanethiosulfonate (228 mg,
1.70 mmol) and 1,11-dibromoundecane (3.3 g, 10.51 mmol)
following procedure iv.
1H NMR (CDCl3): 3.41 (t, J=6.8 Hz,
2H), 3.33 (s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.89–1.82 (m, 2H),
1.80–1.73 (m, 2H), 1.41 (m, 4H), and 1.29 (m, 10H);
13C NMR
(CDCl3): 50.9, 36.7, 34.4, 33.0, 29.7, 29.6, 29.2, 29.0, 28.8, and
28.4.
N,N,N-Trimethyl-11-(methylsulfonylthio)undecan-1-
aminium bromide (AMTS11, 130 mg, 41%) was obtained
from trimethylamine (33% w/w solution in ethanol, 60 mL) and S-
11-bromoundecyl methanesulfonothioate (270 mg, 0.78 mmol)
following procedure vi.
1H NMR (CDCl3): 3.63–3.59 (m, 2H),
3.47 (s, 9H), 3.35 (s, 3H), 3.18 (t, J=7.4 Hz, 2H), 1.80–1.73 (m,
4H), and 1.42–1.28 (m, 14H);
13C NMR (DMSO-d6): 65.9, 52.8,
50.8, 36.2, 29.5, 29.4, 29.2, 29.1, 28.6, 26.4, and 22.7.
N,N,N-Trimethyl-12-(methylsulfonylthio)dodecan-1-
aminium bromide (AMTS12, 47 mg, 13%) was obtained from
sodium methanethiosulfonate (114 mg, 0.85 mmol) and 12-
bromo-N,N,N-trimethyldodecan-1-aminium bromide (387 mg,
0.91 mmol) following procedure v.
1H NMR (CDCl3): 3.62–3.57
(m, 2H), 3.47 (s, 9H), 3.34 (s, 3H), 3.18 (t, J=7.4 Hz, 2H), 1.81–
1.71 (m, 4H), and 1.46–1.27 (m, 16H);
13C NMR (CDCl3): 67.3,
53.6, 50.9, 36.7, 29.6, 29.4, 29.0, 28.7, 26.3, and 23.4.
13-Hydroxy-N,N,N-trimethyltridecan-1-aminium bro-
mide (1.33 g, 80%) was obtained from trimethylamine (33% w/w
solution in ethanol, 60 mL) and 13-bromotridecan-1-ol (1.16 g,
4.15 mmol) following procedure i.
1H NMR (DMSO-d6): 4.34 (t,
J=5.1 Hz, 1H), 3.37 (m, 2H), 3.30–3.25 (m, 2H), 3.05 (s, 9H),
1.70–1.60 (m, 2H), 1.42–1.27 (m, 2H), and 1.27–1.20 (m, 18H);
13C NMR (DMSO-d6): 65.9, 61.4, 52.8, 33.2, 29.8, 29.7, 29.5,
29.2, 26.4, 26.2, and 22.7.
13-Bromo-N,N,N-trimethyltridecan-1-aminium bro-
mide (610 mg, 71%) was obtained from hydrobromic acid
(48% aqueous, 20 mL) and 13-hydroxy-N,N,N-trimethyltridecan-
1-aminium bromide (728 mg, 2.15 mmol) following procedure ii.
1H NMR (DMSO-d6): 3.53 (t, J=6.6 Hz, 2H), 3.29–3.24 (m, 2H),
3.04 (s, 9H), 1.82–1.75 (m, 2H), 1.66 (m, 2H), and 1.38–1.26 (m,
18H);
13C NMR (DMSO-d6): 65.9, 52.8, 36.0, 32.9, 29.7, 29.6,
29.5, 29.2, 28.8, 28.2, 26.4, and 22.7.
N,N,N-Trimethyl-13-(methylsulfonylthio)tridecan-1-
aminium bromide (AMTS13, 320 mg, 63%) was obtained
from sodium methanethiosulfonate (200 mg, 1.49 mmol) and 13-
bromo-N,N,N-trimethyltridecan-1-aminium bromide (470 mg,
1.17 mmol) following procedure v.
1H NMR (DMSO-d6): 3.49
(s, 3H), 3.27–3.23 (m, 2H), 3.17 (t, J=7.4 Hz, 2H), 3.02 (s, 9H),
1.70–1.60 (m, 4H), and 1.36–1.20 (m, 18H);
13C NMR (DMSO-
d6): 65.9, 52.8, 50.8, 36.2, 29.7, 29.6, 29.5, 29.2, 29.1, 28.6, 26.4,
and 22.7; Anal. Calcd (%) for C17H38NO2S2 BrNH2O: C 45.32, H
8.95, and N 3.11; Found: C 45.28, H 8.83, and N 3.08.
S-14-Bromotetradecyl methanesulfonothioate (340 mg,
88%) was obtained from sodium methanethiosulfonate (134 mg,
1.00 mmol) and 1,14-dibromotetradecane (1.00 g, 2.81 mmol)
following procedure iv.
1H NMR (CDCl3): 3.41 (t, J=6.8 Hz,
2H), 3.23 (s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.89–1.82 (m, 2H),
1.80–1.73 (m, 2H), 1.42 (m, 4H), and 1.26 (m, 16H);
13C NMR
(CDCl3): 50.9, 36.7, 34.4, 33.1, 29.8, 29.7, 29.6, 29.2, 29.0, 28.8,
and 28.4.
N,N,N-Trimethyl-14-(methylsulfonylthio)tetradecan-
1-aminium bromide (AMTS14, 120 mg, 35%) was obtained
from trimethylamine (33% w/w solution in ethanol, 25 mL) and S-
14-bromotetradecyl methanesulfonothioate (300 mg, 0.77 mmol)
following procedure vi.
1H NMR (DMSO-d6): 3.49 (s, 3H), 3.29–
3.24 (m, 2H), 3.17 (t, J=7.4 Hz, 2H), 3.03 (s, 9H), 1.70–1.59 (m,
4H), and 1.36–1.20 (m, 20H);
13C NMR (DMSO-d6): 65.9, 52.8,
50.8, 36.2, 29.7, 29.6, 29.5, 29.2, 29.1, 28.6, 26.4, and 22.7.
15-Bromo-N,N,N-trimethylpentadecan-1-aminium
bromide (930 mg, 91%) was obtained from hydrobromic acid
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can-1-aminium bromide (877 mg, 2.39 mmol) following proce-
dure ii.
1H NMR (CDCl3): 3.61–3.57 (m, 2H), 3.48 (s, 9H), 3.42 (t,
J=6.8 Hz, 2H), 1.89–1.82 (m, 2H), 1.79–1.70 (m, 2H), and 1.46–
1.23 (m, 22H);
13C NMR (CDCl3): 67.2, 53.6, 34.4, 33.0, 29.8,
29.7, 29.6, 29.5, 29.0, 28.4, 26.4, and 23.4.
N,N,N-Trimethyl-15-(methylsulfonylthio)pentadecan-
1-aminium bromide (AMTS15, 180 mg, 20%) was obtained
from sodium methanethiosulfonate (281 mg, 2.09 mmol) and 15-
bromo-N,N,N-trimethylpentadecan-1-aminium bromide (827 mg,
1.93 mmol) following procedure v.
1H NMR (DMSO-d6): 3.49 (s,
3H), 3.26–3.22 (m, 2H), 3.17 (t, J=7.2 Hz, 2H), 3.02 (s, 9H),
1.70–1.59 (m, 4H), and 1.37–1.20 (m, 22H);
13C NMR (DMSO-
d6): 65.9, 52.8, 50.8, 36.2, 29.7, 29.6, 29.5, 29.2, 29.1, 28.6, 26.4,
and 22.7.
16-Bromo-N,N,N-trimethylhexadecan-1-aminium bro-
mide (800 mg, 84%) was obtained hydrobromic acid (48%
aqueous, 20 mL) and 16-hydroxy-N,N,N-trimethylhexadecan-1-
aminium bromide (820 mg, 2.15 mmol) following procedure ii.
1H NMR (CDCl3): 3.62–3.57 (m, 2H), 3.48 (s, 9H), 3.41 (t,
J=6.8 Hz, 2H), 1.89–1.82 (m, 2H), 1.79–1.71 (m, 2H), and 1.46–
1.22 (m, 24H);
13C NMR (CDCl3): 67.2, 53.6, 34.4, 33.0, 29.8,
29.7, 29.6, 29.5, 29.0, 28.4, 26.4, and 23.4.
N,N,N-Trimethyl-16-(methylsulfonylthio)hexadecan-
1-aminium bromide (AMTS16, 120 mg, 21%) was obtained
from sodium methanethiosulfonate (160 mg, 1.20 mmol) and 16-
bromo-N,N,N-trimethylhexadecan-1-aminium bromide (564 mg,
1.27 mmol) following procedure v.
1H NMR (CDCl3): 3.62–3.58
(m, 2H), 3.47 (s, 9H), 3.34 (s, 3H), 3.18 (t, J=7.4 Hz, 2H), 1.80–
1.70 (m, 4H), and 1.46–1.22 (m, 24H);
13C NMR (CDCl3): 67.1,
53.6, 50.9, 36.8, 29.8, 29.7, 29.6, 29.5, 29.4, 29.1, 28.8, 26.4, and
23.4.
S-17-Bromoheptadecyl methanesulfonothioate (36 mg,
93%) was obtained from 1,17-dibromoheptadecane (113 mg,
0.28 mmol) and sodium methanethiosulfate (12 mg, 0.09 mmol)
following the general procedure iv.
1H NMR (CDCl3): 3.41 (t,
J=6.8 Hz, 2H), 3.32 (s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.88–1.81
(m, 2H), 1.79–1.72 (m, 2H), and 1.42–1.20 (m, 26H);
13C NMR
(CDCl3): 50.9, 36.8, 34.4, 33.1, 29.9, 29.8, 29.7, 29.6, 29.2, 29.0,
28.8, and 28.4.
N,N,N-Trimethyl-17-(methylsulfonylthio)heptadecan-
1-aminium bromide (AMTS17, 5 mg, 12%) was obtained
from trimethylamine (33% w/w solution in ethanol, 2.6 mL) and
S-17-bromoheptadecyl methanesulfonothioate (34 mg,
0.08 mmol) following general procedure vi.
1H NMR (CDCl3):
3.59–3.56 (m, 2H), 3.47 (s, 9H), 3.33 (s, 3H), 3.17 (t, J=7.4 Hz,
2H), 1.80–1.71 (m, 4H), and 1.46–1.22 (m, 26H);
13C NMR
(CDCl3): 67.3, 53.6, 50.9, 36.8, 29.8, 29.7, 29.6, 29.4, 29.2, 28.8,
26.4, and 23.4; Anal. Calcd (%) for C21H46NO2S2 BrNH2O: C
49.78, H 9.55, and N 2.76; Found: C 49.41, H 9.57, and N 2.75.
S-18-Bromooctadecyl methanesulfonothioate (256 mg,
63%) was obtained from 1,18-dibromooctadecane (1.143 g,
2.77 mmol) and sodium methanethiosulfate (123 mg, 0.92 mmol)
following procedure iv.
1H NMR (CDCl3): 3.41 (t, J=6.8 Hz,
2H), 3.32 (s, 3H), 3.17 (t, J=7.2 Hz, 2H), 1.89–1.82 (m, 2H),
1.80–1.73 (m, 2H), and 1.42–1.26 (m, 28H);
13C NMR (CDCl3):
50.9, 36.7, 34.4, 33.1, 29.9, 29.8, 29.7, 29.6, 29.2, 29.0, 28.8, and
28.4.
N,N,N-Trimethyl-18-(methylsulfonylthio)octadecan-1-
aminium bromide (AMTS18, 223 mg, 93%) was obtained
from trimethylamine (33% w/w solution in ethanol, 14 mL) and S-
18-bromooctadecyl methanesulfonothioate (211 mg, 0.48 mmol)
following procedure vi.
1H NMR (CDCl3): 3.60–3.56 (m, 2H),
3.48 (s, 9H), 3.33 (s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.80–1.71 (m,
4H), and 1.43–1.22 (m, 28H);
13C NMR (CDCl3): 67.2, 53.6, 50.9,
36.8, 29.8, 29.7, 29.6, 29.5, 29.2, 28.8, 26.4, and 23.4.
S-19-Bromononadecyl methanesulfonothioate (64 mg,
96%) was obtained from 1,19-dibromononadecane (179 mg,
0.42 mmol) and sodium methanethiosulfate (19 mg, 0.14 mmol)
following general procedure iv.
1H NMR (CDCl3): 3.40 (t,
J=6.8 Hz, 2H), 3.31 (s, 3H), 3.16 (t, J=7.4 Hz, 2H), 1.88–1.81
(m, 2H), 1.79–1.72 (m, 2H) and 1.41–1.22 (m, 30H);
13C NMR
(CDCl3): 50.9, 36.7, 34.4, 33.1, 29.9, 29.8, 29.7, 29.6, 29.2, 29.0,
28.8, and 28.4.
N,N,N-Trimethyl-19-(methylsulfonylthio)nonadecan-
1-aminium bromide (AMTS19, 26 mg, 34%) was obtained
from trimethylamine (33% w/w solution in ethanol, 25 mL) and S-
19-bromononadecyl methanesulfonothioate (68 mg, 0.15 mmol)
following general procedure vi.
1H NMR (CDCl3): 3.60–3.55 (m,
2H), 3.47 (s, 9H), 3.33 (s, 3H), 3.17 (t, J=7.4 Hz, 2H), 1.80–1.70
(m, 4H), and 1.46–1.22 (m, 30H);
13C NMR (CDCl3): 67.4, 53.7,
50.9, 36.8, 29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 28.8, 26.4, and 23.4.
S-20-Bromoicosyl methanesulfonothioate (219 mg, 62%)
was obtained from 1,20-dibromoicosane (1.01 g, 2.29 mmol) and
sodium methanethiosulfate (103 mg, 0.76 mmol) following general
procedure iv.
1H NMR (CDCl3): 3.40 (t, J=6.8 Hz, 2H), 3.32 (s,
3H), 3.16 (t, J=7.4 Hz, 2H), 1.88–1.81 (m, 2 H), 1.79–1.72 (m,
2H), and 1.42–1.25 (m, 32H);
13C NMR (CDCl3): 50.9, 36.7, 34.4,
33.1, 29.9, 29.8, 29.7, 29.6, 29.2, 29.0, 28.8, and 28.4.
N,N,N-Trimethyl-20-(methylsulfonylthio)icosan-1-ami-
nium bromide (AMTS20, 117 mg, 82%) was obtained from
trimethylamine (33% w/w solution in ethanol, 10 mL) and S-20-
bromoicosyl methanesulfonothioate (129 mg, 0.27 mmol) following
generalprocedurevi.
1HNMR(CDCl3):3.60–3.56(m,2H),3.48(s,
9H), 3.33 (s, 3H), 3.17 (t, J=7.2 Hz, 2H), 1.80–1.73 (m, 4H), and
1.46–1.24 (m, 32H);
13C NMR (CDCl3): 67.4, 53.6, 50.9, 36.8,
29.9, 29.8, 29.7, 29.6, 29.4, 29.2, 28.8, 26.4, and 23.4.
13-[Methoxythio(d3)]-N,N,N-trimethyltridecan-1-ami-
nium bromide. To a 5-mm NMR tube containing 0.6 mL of
CD3OD was added 8.6 mg of Na metal (623 mMo fC D 3ONa,
0.373 mmol). Sodium metal was allowed to dissolve completely
and the NMR tube was kept at room temperature for one hour.
AMTS13 (5 mg, 0.011 mmol) was then added in one portion to
the NMR tube. Soon after the addition
1H NMR spectrum of the
resultant mixture was acquired and showed complete disappear-
ance of the starting material. The spectrum for the crude product
is as follows:
1H NMR (CD3OD) d 3.30–3.44 (m, 2H), 3.12 (s, 9H), 2.66 (t,
J=7.2 Hz, 2H), 1.78 (m, 2H), 1.66 (m, 2H), and 1.30–1.40 (m,
18H);
13C NMR (CD3OD) d 66.6, 62.2, 52.3, 48.6, 38.5, 29.5,
29.4, 29.3, 29.1, 29.0, 28.2, 26.2, and 22.8.
Measurement of AChE inhibition
Greenbugs, soybean aphids, or fruit flies were stored frozen at
220uC, as were crude preparations of washed human red blood
cell membranes prepared as described elsewhere [47]. For
experiments involving exposure to test compounds and subsequent
dialysis, the insect samples were homogenized twice for 10 seconds
each in ground glass homogenizers containing 100 volumes of ice-
cold 0.09% NaCl, 0.1 M sodium phosphate (pH 7.4) and 0.1%
BSA. RBC samples were prepared similarly but by sonication for 5
to 10 sec in buffer with added Triton X-100 (0.5% v/v). In both
cases the resulting fine suspensions were diluted 30-fold in the
homogenization buffer before treatments and assays, and they
were thoroughly re-suspended by vortex mixing as each aliquot
was transferred to the reaction tubes. Strict attention to this
procedure resulted in duplicate agreements within 62% for the
greenbug AChE activity and within 61% for RBC AChE activity.
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pounds by size-exclusion chromatography, insect and red cell
samples were homogenized for 2 min in 0.1 M sodium phosphate
(pH 7.4) and centrifuged at 15,0006g for 15 min to obtain
supernatants for inhibitor exposure or enzyme assay. In certain
experiments, 0.3% (v/v) Triton X-100 was added to the buffer in
order to solubilize the enzyme (extraction efficiency 85–90%). This
procedure did not increase total AChE activity or alter the
percentage of inhibition by the methanethiosulfonate agents
tested.
Experiments calling for sample exposure to inhibitors or
reactivating reagents typically involved one or more steps to
separate the small molecules from the enzyme before determina-
tions of AChE activity. In the initial phases of the study, these steps
utilized Centricon Spin Columns containing Sepharose G-10 size-
exclusion gel-filtration resin, which provided very rapid separation
during 10 min of centrifugation at 10006g. This procedure,
followed by 50-fold dilution before assay (with 0.1 M sodium
phosphate buffer, pH 7.4), enhanced throughput for screening
purposes. Final data reported in this article, however, were
obtained after dialysis for 16–24 hr against two changes of the
buffer in more than 100-fold excess. For present purposes this
standard biochemical procedure was validated by control
experiments demonstrating its ability to remove all traces of
inhibitory activity as tested with sentinel samples of AChE.
The AChE assays were based on an established radiometric
technique in which product (
3H-labeled acetic acid) liberated
enzymatically from substrate (
3H-labeled acetylcholine, 50 nCi in
a final reaction volume of 100 mL at pH 7.4) is partitioned into
4 mL of toluene-isoamyl alcohol (5:1, v/v) with scintillation fluor
[48,49]. As a rule, the assays were performed with substrate in a
concentration of 0.1 mM. This condition allowed maximum
sensitivity (active samples more than 10 times the buffer-only
blanks) with small samples (500 mg wet weight equivalent) and
high temporal resolution (assay times as short as 5 min). Also,
because of the low substrate concentrations a reversible 50%
inhibition was expected to occur at concentrations near the true Ki.
When necessary, substrate concentration was adjusted by diluting
stock material (99 mCi/mM) with unlabelled acetylcholine
chloride. Assay duration, at room temperature, was rigorously
controlled to ensure that signal was robust (.5 times blank value)
and remained linear with respect to time and amount of sample
present (typical conditions, 5 min for concentrated samples or up
to 4 hours for highly dilute or low activity samples).
AChE Reactivation by b-Mercaptoethanol
Reactivation by BME was examined with AChE samples that
were exposed for 1 hr to an inhibitor at 6.0 mM final
concentration, followed by dialysis overnight against two changes
of .100 volumes of 0.1 M sodium phosphate buffer at pH 7.4.
This treatment led to 99% inhibition of the greenbug enzyme and
43% inhibition of the red cell enzyme. Treated samples were
exposed to BME at a final concentration of 100 mM for 0.5, 1 or
2 hr, followed by a second overnight dialysis against the phosphate
buffer.
Multiple Molecular Dynamics Simulations of AChE
Complexes
Multiple molecular dynamics simulations (MMDSs) were
performed using the PMEMD module of the AMBER 8.0
program [50] with a revised force field (to be published) that is
based on the second-generation AMBER force field
(frcmod.ff99SB) [51]. The topology and coordinate files were
generated by the PREP, LINK, EDIT, and PARM modules of the
AMBER 5.0 program [50]. All simulations used (1) a dielectric
constant of 1.0, (2) the Berendsen coupling algorithm [52], (3) a
periodic boundary condition at a constant temperature of 300 K
and a constant pressure of 1 atm with isotropic molecule-based
scaling, (4) the Particle Mesh Ewald method to calculate long-
range electrostatic interactions [53], (5) a time step of 1.0 fs, (6) the
SHAKE-bond-length constraints applied to all the bonds involving
the H atom, (7) saving the image closest to the middle of the
‘‘primary box’’ to the restart and trajectory files, (8) unformatted
restart file, and (9) default values of all other inputs of the PMEMD
module. All simulations were performed on eight Apple Mac Pros
each equipped with eight Intel Woodcrest cores at a clock rate of
3.0 GHz.
The atomic charges of AMTS13 and AMTS17 were obtained
according to the RESP procedure [54] with ab initio calculations at
the HF/6-31G*//HF/6-31G* level using the Gaussian98 program
[55]. The human and greenbug AChE structures were taken from
the coordinate files with Protein Data Bank codes of 1B41 [17] and
2HCP [9],respectively.Forthehumanenzyme,His447 and His284
were treated as HID; His223 and His387 were treated as HIE; all
other His residues were treated as HIP. For the greenbug AChE,
His45, His411, His442, and His500 were treated as HID; all other
His residues were treated as HIP. The initial structure of the
inhibitor-bound AChE was generated by manually inserting
AMTS13 or AMTS17 in its fully extended conformation into the
active site of the respective AChE that was devoid of fasciculin,
acetylcholine, water molecules, and ions. The methanethiosulfonate
and aminium moieties of AMTS13 and AMTS17 were placed at
the bottom of the active site of the human and greenbug AChEs,
respectively. The resulting complexes were refined by a two-step
energy minimization. Step 1 used (1) a positional constraint applied
to AChE (IBELLY=1), (2) 100 cycles of steepest-descent minimi-
zation followed by 400 cycles of conjugate-gradient minimization,
and (3) a dielectric constant of 1.0. Step 2 used (1) no positional
constraint (IBELLY=0), (2) 10 cycles of steepest-descent minimi-
zation followed by 490 cycles of conjugate-gradient minimization,
and (3) a dielectric constant of 1.0.
The energy-minimized AChE complexes were solvated with
14,357 and 17,549 TIP3P water molecules [56], respectively
(EDIT input: 216000 water molecules, 0.4170 for the charge on
the water hydrogen atom, removing any water molecule whose
oxygen atom is closer than 2.2 A ˚ to any solute atom, removing any
water molecule whose hydrogen atom is closer than 2.0 A ˚ to any
solute atom, and removing any water molecule that is farther than
8.2 A ˚ along the x-, y-, and z-axes from any atom of solute). The
solvated human and insect AChE complex systems had a total of
51,288 and 61,205 atoms; they were first energy-minimized for
200 steps to remove close van der Waals contacts in the system,
slowly heated to 300 K (10 K/ps under constant temperature and
volume). Thirteen 10-ns-long simulations (each with a unique seed
number for starting velocities) were carried out for the human
AChE complex whereas four 10-ns-long simulations were carried
out for the insect complex.
For each simulation, a time-average structure was obtained
from 1000 trajectories collected at 1.0-ps intervals during the last
1-ns period using the CARNAL module of AMBER 5.0. For the
13 simulations of the human complex, the distances of the Ser203
hydroxyl oxygen atom to the AMTS13 thiol sulfur atom
calculated from the initial structure and the 13 time-average
structures were 4.1, 6.2, 6.4, 9.6, 18.9, 8.5, 5.8, 13.5, 8.7, 8.9, 10.4,
11.0, 4.7, and 8.1 A ˚, respectively, indicating good sampling
achieved by the 10-ns-long MMDSs. With water molecules
stripped off, the average structure with the shortest distance was
then energy minimized (performing 50 cycles of steepest-descent
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zation using a dielectric constant of 80.0). The energy-minimized
average structure was chosen as the MMDS-refined 3D model.
Likewise, for the greenbug AChE complex, the distance between
the Cys289 sulfur atom and the AMTS17 thiol sulfur atom was
used to generate the MMDS-refined 3D model, and the distances
calculated from the initial structure and the four time-average
structures were 6.5, 3.8, 7.5, 5.5, and 8.9 A ˚, respectively. The
coordinates of the initial and the MMDS-refined 3D models of the
human and greenbug AChE complexes are provided in Datasets
S1, S2, S3, S4 of Supporting Information, respectively.
Supporting Information
Dataset S1 The initial model of the human AChE in complex
with AMTS13
Found at: doi:10.1371/journal.pone.0004349.s001 (0.23 MB
TXT)
Dataset S2 The refined model of the human AChE in complex
with AMTS13
Found at: doi:10.1371/journal.pone.0004349.s002 (0.23 MB
TXT)
Dataset S3 The initial model of the greenbug AChE in complex
with AMTS17
Found at: doi:10.1371/journal.pone.0004349.s003 (0.24 MB
TXT)
Dataset S4 The refined model of the greenbug AChE in
complex with AMTS17
Found at: doi:10.1371/journal.pone.0004349.s004 (0.24 MB
TXT)
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